Immunosuppression News and Research

RSS

Immunosuppression involves an act that reduces the activation or efficacy of the immune system. Some portions of the immune system itself have immuno-suppressive effects on other parts of the immune system, and immunosuppression may occur as an adverse reaction to treatment of other conditions.

Fecal microbiota transplantation officially recommended for effective treatment of C. difficile infection

The transplantation of faecal microbiota from a healthy donor has been shown in recent clinical studies to be a safe and highly effective treatment for recurrent Clostridium difficile (C. difficile) infection and is now recommended in European treatment guidelines.

29 Sep 2014

Asterias receives clearance from FDA to initiate Phase 1/2a clinical trial of AST-OPC1

Asterias Biotherapeutics Inc. has received clearance from the U.S. Food and Drug Administration to initiate a Phase 1/2a clinical trial of its product, AST-OPC1, in patients with complete cervical spinal cord injury.

27 Aug 2014

Houston Methodist researchers receive $1.6M from NIH to study pathological antibodies

Transplant immunologists at the Houston Methodist Research Institute will receive about $1.6 million over four years from the National Institute of Allergy and Infectious Diseases to study pathological antibodies produced from activated memory B cells during the chronic rejection of organ transplants.

20 Aug 2014

Clinical trial to investigate safety of neural stem cell transplantation in patients with spinal cord injuries

Researchers at the University of California, San Diego School of Medicine have launched a clinical trial to investigate the safety of neural stem cell transplantation in patients with chronic spinal cord injuries.

12 Aug 2014

Induced immunorejection may eliminate tumors post-cell transplantation

Recent studies have shown that transplanting induced pluripotent stem cell-derived neural stem cells (iPS-NSCs) can promote functional recovery after spinal cord injury in rodents and non-human primates. However, a serious drawback to the transplantation of iPS-NSCs is the potential for tumor growth, or tumorogenesis, post-transplantation.

7 Aug 2014

Drug used for treating rheumatoid arthritis can improve health of kidney transplant recipients

UC San Francisco is the lead institution on a new seven-year, $17 million multicenter study funded by the National Institutes of Health to determine if certain immune system cells and/or a drug now used for treating rheumatoid arthritis can be effective in improving and maintaining the long-term health of kidney transplant recipients.

5 Aug 2014

Pneumococcal pneumonia mortality falling

Between 2000 and 2013 there has been an increase in the early prescription of antibiotics and use of combination therapy in patients with pneumococcal pneumonia, researchers report.

28 Jul 2014

Envarsus gets marketing authorization from EC for treatment of kidney and liver transplant patients

Veloxis Pharmaceuticals A/S and Chiesi Farmaceutici S.p.A. today announced that the European Commission (EC) has granted marketing authorization for Envarsus for the prevention of organ rejection in adult kidney and liver transplant patients in the European Union.

28 Jul 2014

Researchers working to develop new drugs for treating chronic inflammatory diseases

Science and industry are collaborating to develop future pharmaceuticals for treating chronic inflammatory diseases. The medicines will combat immunological processes that have gone wrong.

25 Jul 2014

Immune marker predicts infection risk in critically ill children with traumatic injuries

Researchers studying critically ill children with traumatic injuries have identified an immune marker that predicts which patients are likely to develop a hospital-acquired infection.

10 Jul 2014

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology.

3 Jul 2014

Findings provide new insights into the basic biology of stem cells

A team of researchers from the University of California, San Diego School of Medicine, Oregon Health & Science University and Salk Institute for Biological Studies has shown for the first time that stem cells created using different methods produce differing cells.

3 Jul 2014

Bone marrow transplantation shows promising results among patients with severe sickle cell disease

Use of a lower intensity bone marrow transplantation method showed promising results among 30 patients (16-65 years of age) with severe sickle cell disease, according to a study in the July 2 issue of JAMA.

1 Jul 2014

HIV-positive people with early-stage cancer less likely to get cancer treatment

HIV-infected people diagnosed with cancer are two to four times more likely to go untreated for their cancer compared to uninfected cancer patients, according to a new, large retrospective study from researchers in Penn Medicine's Abramson Cancer Center and the National Cancer Institute (NCI) published online ahead of print in the Journal of Clinical Oncology.

1 Jul 2014

Cubist Pharmaceuticals' SIVEXTRO receives FDA approval for treatment of ABSSSI

Cubist Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration approved SIVEXTRO (tedizolid phosphate) for the treatment of adult acute bacterial skin and skin structure infections (ABSSSI).

21 Jun 2014

Cubist Pharmaceuticals publishes positive results from Phase 3 clinical trial of SIVEXTRO

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that The Lancet Infectious Diseases published online the positive results from ESTABLISH-2, a pivotal Phase 3 clinical trial of the investigational antibiotic SIVEXTRO™ (tedizolid phosphate), which is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and complicated skin and soft tissue infections (cSSTI).

9 Jun 2014

Immunosuppression News and Research

Further Reading

Fecal microbiota transplantation officially recommended for effective treatment of C. difficile infection

Asterias receives clearance from FDA to initiate Phase 1/2a clinical trial of AST-OPC1

Houston Methodist researchers receive $1.6M from NIH to study pathological antibodies

Clinical trial to investigate safety of neural stem cell transplantation in patients with spinal cord injuries

Induced immunorejection may eliminate tumors post-cell transplantation

Drug used for treating rheumatoid arthritis can improve health of kidney transplant recipients

Pneumococcal pneumonia mortality falling

Envarsus gets marketing authorization from EC for treatment of kidney and liver transplant patients

Researchers working to develop new drugs for treating chronic inflammatory diseases

Immune marker predicts infection risk in critically ill children with traumatic injuries

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

Findings provide new insights into the basic biology of stem cells

Bone marrow transplantation shows promising results among patients with severe sickle cell disease

HIV-positive people with early-stage cancer less likely to get cancer treatment

Cubist Pharmaceuticals' SIVEXTRO receives FDA approval for treatment of ABSSSI

Cubist Pharmaceuticals publishes positive results from Phase 3 clinical trial of SIVEXTRO

Scientists develop new molecule for monitoring drug concentration

Single-cell genomics study confirms that immune cells produce steroids

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

High doses of steroids fail to improve outcomes in pediatric liver disease

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News